Literature DB >> 29106028

Association of High Anti-Cyclic Citrullinated Peptide Seropositivity and Lean Mass Index With Low Bone Mineral Density in Rheumatoid Arthritis.

Katherine D Wysham1, Dolores M Shoback2, John B Imboden1, Patricia P Katz1.   

Abstract

OBJECTIVE: Osteoporotic fractures are associated with high morbidity and mortality. Persons with rheumatoid arthritis (RA) have twice the risk of osteoporosis-related fracture than age-matched controls, the causes for which remain unknown. We investigated contributions of RA characteristics, medication use, and body composition to low bone mineral density (BMD) in patients with RA.
METHODS: Data were from the Arthritis, Body Composition, and Disability Study (n = 138; 82 women, 56 men). Demographic, clinical, laboratory, and functional variables were collected at study visits. Body composition (fat, lean muscle, and BMD) was measured by dual x-ray absorptiometry. Linear regression analyses evaluated the association between predictors and femoral neck BMD.
RESULTS: Average disease duration was 19 years, 70% of patients were rheumatoid factor positive, and 55% were high-positive anti-cyclic citrullinated peptide (anti-CCP). Age and high anti-CCP positivity were negatively associated with BMD after controlling for other variables (β = -0.003 and -0.055, respectively, P < 0.05). Appendicular lean mass index (ALMI) was positively associated with BMD (β = 0.053, P < 0.0001). In high anti-CCP positivity participants, increasing anti-CCP levels were associated with a negative linear trend in BMD (β = -0.011, P = 0.026).
CONCLUSION: High anti-CCP positivity and ALMI were strongly associated with BMD in patients with RA. The linear relationship of anti-CCP levels with lower BMD supports the hypothesis that processes specific to RA negatively impact BMD. In contrast, ALMI was positively associated with BMD, emphasizing the importance of this potentially modifiable risk factor. Our findings highlight the complicated interplay of RA disease-specific and functional factors and their impact on bone mass.
© 2017, American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29106028      PMCID: PMC5936473          DOI: 10.1002/acr.23440

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   4.794


  49 in total

1.  A multicenter cross sectional study on bone mineral density in rheumatoid arthritis. Italian Study Group on Bone Mass in Rheumatoid Arthritis.

Authors:  L Sinigaglia; A Nervetti; Q Mela; G Bianchi; A Del Puente; O Di Munno; B Frediani; F Cantatore; R Pellerito; S Bartolone; G La Montagna; S Adami
Journal:  J Rheumatol       Date:  2000-11       Impact factor: 4.666

2.  Test-retest reliability of four physical activity measures used in population surveys.

Authors:  W J Brown; S G Trost; A Bauman; K Mummery; N Owen
Journal:  J Sci Med Sport       Date:  2004-06       Impact factor: 4.319

3.  The International Physical Activity Questionnaire (IPAQ): a study of concurrent and construct validity.

Authors:  Maria Hagströmer; Pekka Oja; Michael Sjöström
Journal:  Public Health Nutr       Date:  2006-09       Impact factor: 4.022

Review 4.  Testosterone supplementation and body composition: results from a meta-analysis of observational studies.

Authors:  G Corona; V A Giagulli; E Maseroli; L Vignozzi; A Aversa; M Zitzmann; F Saad; E Mannucci; M Maggi
Journal:  J Endocrinol Invest       Date:  2016-05-30       Impact factor: 4.256

5.  Plasma testosterone concentrations in asthmatic men treated with glucocorticoids.

Authors:  I R Reid; H K Ibbertson; J T France; J Pybus
Journal:  Br Med J (Clin Res Ed)       Date:  1985-08-31

6.  Association between lean mass, fat mass, and bone mineral density: a meta-analysis.

Authors:  Lan T Ho-Pham; Uyen D T Nguyen; Tuan V Nguyen
Journal:  J Clin Endocrinol Metab       Date:  2013-01-01       Impact factor: 5.958

7.  Osteoporosis management in patients with rheumatoid arthritis: Evidence for improvement.

Authors:  Daniel H Solomon; Jeffrey N Katz; Danielle Cabral; Amanda R Patrick; Jack F Bukowski; Jonathan S Coblyn
Journal:  Arthritis Rheum       Date:  2006-12-15

8.  Bone mineral density in the hand as a predictor for mortality in patients with rheumatoid arthritis.

Authors:  Christina Book; Jakob Algulin; Jan-Ake Nilsson; Tore Saxne; Lennart Jacobsson
Journal:  Rheumatology (Oxford)       Date:  2009-06-24       Impact factor: 7.580

9.  Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis.

Authors:  Annette H M van der Helm-van Mil; Kirsten N Verpoort; Ferdinand C Breedveld; René E M Toes; Tom W J Huizinga
Journal:  Arthritis Res Ther       Date:  2005-06-14       Impact factor: 5.156

10.  Identification of a novel chemokine-dependent molecular mechanism underlying rheumatoid arthritis-associated autoantibody-mediated bone loss.

Authors:  Akilan Krishnamurthy; Vijay Joshua; Aase Haj Hensvold; Tao Jin; Meng Sun; Nancy Vivar; A Jimmy Ytterberg; Marianne Engström; Cátia Fernandes-Cerqueira; Khaled Amara; Malin Magnusson; Gustaf Wigerblad; Jungo Kato; Juan Miguel Jiménez-Andrade; Kerry Tyson; Stephen Rapecki; Karin Lundberg; Sergiu-Bogdan Catrina; Per-Johan Jakobsson; Camilla Svensson; Vivianne Malmström; Lars Klareskog; Heidi Wähämaa; Anca I Catrina
Journal:  Ann Rheum Dis       Date:  2015-11-26       Impact factor: 19.103

View more
  12 in total

1.  Increased risk of osteoporotic vertebral fracture in rheumatoid arthritis patients with new-onset cardiovascular diseases: a retrospective nationwide cohort study in Taiwan.

Authors:  W-J Hong; W Chen; K-J Yeo; P-H Huang; D-Y Chen; J-L Lan
Journal:  Osteoporos Int       Date:  2019-05-24       Impact factor: 4.507

2.  Low cumulative disease activity is associated with higher bone mineral density in a majority Latinx and Asian US rheumatoid arthritis cohort.

Authors:  Katherine D Wysham; Jane Shofer; Gabriella Lui; Laura Trupin; James S Andrews; Dennis M Black; Jonathan Graf; Dolores M Shoback; Patricia P Katz
Journal:  Semin Arthritis Rheum       Date:  2022-01-31       Impact factor: 5.532

Review 3.  The effect of disease-modifying anti-rheumatic drugs on skeletal muscle mass in rheumatoid arthritis patients: a systematic review with meta-analysis.

Authors:  Thales R Hein; Leonardo Peterson; Barbara J Bartikoski; Juliana Portes; Rafaela C Espírito Santo; Ricardo M Xavier
Journal:  Arthritis Res Ther       Date:  2022-07-19       Impact factor: 5.606

4.  Association of high titers of anti-carbamylated protein antibodies with decreased bone mineral density in early arthritis patients.

Authors:  Cristina Regueiro; Ana M Ortiz; Maria Dolores Boveda; Santos Castañeda; Isidoro Gonzalez-Alvaro; Antonio Gonzalez
Journal:  PLoS One       Date:  2018-08-17       Impact factor: 3.240

5.  Sex differences in frailty and its association with low bone mineral density in rheumatoid arthritis.

Authors:  Katherine D Wysham; Dolores M Shoback; James S Andrews; Patricia P Katz
Journal:  Bone Rep       Date:  2020-05-22

6.  Anti-citrullinated protein antibodies are associated with osteopenia but not with pain at diagnosis of rheumatoid arthritis: data from the BARFOT cohort.

Authors:  Ingiäld Hafström; Sofia Ajeganova; Kristina Forslind; Björn Svensson
Journal:  Arthritis Res Ther       Date:  2019-02-04       Impact factor: 5.156

7.  Distinct biomarkers for different bones in osteoporosis with rheumatoid arthritis.

Authors:  T Tomizawa; H Ito; K Murata; M Hashimoto; M Tanaka; K Murakami; K Nishitani; M Azukizawa; A Okahata; K Doi; M Saito; M Furu; M Hamaguchi; T Mimori; S Matsuda
Journal:  Arthritis Res Ther       Date:  2019-07-15       Impact factor: 5.156

8.  Impact of Anti-Citrullinated Protein Antibodies on Progressive Systemic Bone Mineral Density Loss in Patients With Early Rheumatoid Arthritis After Two Years of Treat-to-Target.

Authors:  Serena Bugatti; Laura Bogliolo; Antonio Manzo; Ludovico De Stefano; Paolo Delvino; Francesca Motta; Carlomaurizio Montecucco
Journal:  Front Immunol       Date:  2021-06-14       Impact factor: 7.561

9.  Anti-CCP-positive patients with RA have a higher 10-year probability of fracture evaluated by FRAX®: a registry study of RA with osteoporosis/fracture.

Authors:  Tien-Tsai Cheng; Shan-Fu Yu; Fu-Mei Su; Yin-Chou Chen; Ben Yu-Jih Su; Wen-Chan Chiu; Chung-Yuan Hsu; Jia-Feng Chen; Chi-Hua Ko; Han-Ming Lai
Journal:  Arthritis Res Ther       Date:  2018-01-30       Impact factor: 5.156

10.  Establishment and verification of an osteoporosis risk model in patients with rheumatoid arthritis: a valuable new model.

Authors:  Xiaobin Yan; Zhenhong Xu; Shilin Li; Lisheng Yan; Guorong Lyu; Zecheng Wang
Journal:  Arch Osteoporos       Date:  2021-01-04       Impact factor: 2.617

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.